Lown-Ganong-Levine Syndrome

Palpitations, dizziness, and shortness of breath are symptoms of these paroxysms.
At higher ventricular rates, syncope may happen, especially if ventricular tachycardia or ventricular fibrillation are started.
In cases of underlying structural heart disease or coronary artery disease, episodes of tachycardia may induce cardiac stress and produce symptoms of chest pain or possibly of hypotension or other hemodynamic instability.
For six months following the occurrence of your most recent episode of syncope, or until the cause of your syncope has been properly diagnosed and treated, if you encounter syncope, you should refrain from operating a motor vehicle, including public transportation.

Book an appointment with your Cardiologist if you experience any of these symptoms or call the emergency number right away if you experience any chest pain or discomfort.

A no longer valid clinical diagnostic, Lown-Ganong-Levine (LGL) syndrome has no distinct anatomic link. There are no specific hazards associated with the diagnosis, however the accessory route makes tachyarrhythmias possible.

Physical examination: Cardiovascular examination may show a fast heart rate during paroxysms of tachycardia.
ECG: To diagnose Lown-Ganong-Levine (LVL) syndrome in an acute situation, a resting electrocardiogram is required.
Laboratory tests measuring serum thyroid-stimulating hormone (TSH) levels, calcium and magnesium levels, and serum electrolytes.
Holter monitor or event recorder to record the rhythm during acute symptomatic episodes in cases where the history suggests recurrent paroxysmal tachycardia.
In some rare circumstances, an implantable loop recorder can be useful.
Posteroanterior and lateral chest films may be indicative of breathlessness.

The objectives of medical treatment in the acute tachycardia scenario include determining the origin of tachycardia and, in symptomatic situations, lowering the heart rate. The reason of tachycardia should determine the course of treatment. Hospitalization is necessary in situations of hemodynamic instability, as is the case with any tachycardia.

There is no medication specifically for LGL. Identification of the tachycardia's underlying cause and effective treatment of this cause are the objectives of therapy.

Beta-blockers: Slow AV nodal conduction and inhibit the chronotropic, inotropic, and vasodilatory reactions to beta-adrenergic stimulation.
Calcium channel blockers: Calcium ion transport across the cell membrane is prevented by calcium channel blockers, which lowers the automaticity and conduction velocity of impulses.
Digoxin: Increases myocardial systolic contractions by acting directly on heart muscle.
Identification of the tachycardia's underlying cause and effective treatment of this cause are the objectives of therapy.